Use of Lactobacillus-GG in paediatric Crohn's disease.
The potential role of luminal bacteria in initiating the abnormal immune response seen in inflammatory bowel disease is stressed by many observations. A defect in mucosal barrier function could allow luminal bacterial antigens to initiate the chronic relapsing inflammation in Crohn's disease. The potential role of luminal bacteria in initiating the abnormal immune response seen in inflammatory bowel disease is stressed by many observations. A pilot study to investigate the possible effect of Lactobacillus GG in children with active Crohn's disease was conducted. Four male patients were enrolled, median age 14.5 years (range 10-18). In terms of clinical outcome, the patients showed significant improvement. In three patients on Lactobacillus GG, it was possible to taper the dose of steroids. Thus, although our data are obviously very preliminary, Lactobacillus GG appears to be effective in improving the clinical status of children with Crohn's disease. A multicentre study is currently being carried out in 7 US University centres in a randomized, double-blind, placebo-controlled fashion to establish the efficacy of this probiotic in children with Crohn's disease.
Guandalini
S
S
Department of Paediatrics, University of Chicago, IL 60637, USA. sguandal@peds.bsd.uchicago.edu
D000293:Adolescent; D002648:Child; D003424:Crohn Disease / Q000628:therapy*; D004311:Double-Blind Method; D006801:Humans; D007778:Lactobacillus; D008297:Male; D015337:Multicenter Studies as Topic; D010865:Pilot Projects; D019936:Probiotics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic